Editas Medicine Stock Forecast

Stock Price Forecast

The 6 analysts that cover Editas Medicine stock have a consensus rating of "Strong Buy" and an average price target of $4.92, which forecasts a 67.35% increase in the stock price over the next year. The lowest target is $3.00 and the highest is $8.00.

Price Target: $4.92 (+67.35%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$3.00	$4.92	$5.00	$8.00
Change	+2.04%	+67.35%	+70.07%	+172.11%

* Price targets were last updated on Mar 10, 2026.

Analyst Ratings

The average analyst rating for Editas Medicine stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Nov '25	Dec '25	Jan '26	Feb '26	Mar '26	Apr '26
Strong Buy	4	4	4	4	4	4
Buy	2	2	2	2	1	1
Hold	5	5	5	5	1	1
Sell	1	1	1	1	0	0
Strong Sell	0	0	0	0	0	0
Total	12	12	12	12	6	6

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Soumit Roy Jones Trading	Jones Trading	Hold → Strong Buy Upgrades $8	Hold → Strong Buy	Upgrades	$8	+172.11%	Mar 10, 2026
Geulah Livshits Chardan Capital	Chardan Capital	Strong Buy Maintains $3.5	Strong Buy	Maintains	$3.5	+19.05%	Mar 9, 2026
Mitchell S. Kapoor HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Reiterates $5	Strong Buy	Reiterates	$5	+70.07%	Sep 5, 2025
Yanan Zhu Wells Fargo	Wells Fargo	Hold Maintains $3 → $4	Hold	Maintains	$3 → $4	+36.05%	Sep 3, 2025
Mitchell S. Kapoor HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Maintains $3 → $5	Strong Buy	Maintains	$3 → $5	+70.07%	Aug 15, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

29.10M

from 40.52M

-28.20%

from 40.52M

Revenue Next Year

18.38M

from 29.10M

-36.83%

from 29.10M

EPS This Year

-1.05

from -1.80

EPS Next Year

-1.00

from -1.05

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	25.54M	19.71M	78.12M	32.31M	40.52M	29.10M	18.38M
Revenue Growth	-71.85%	-22.83%	296.32%	-58.64%	25.40%	-28.20%	-36.83%
EPS	-2.85	-3.21	-2.02	-2.88	-1.80	-1.05	-1.00
EPS Growth	-	-	-	-	-	-	-
Forward PE	-	-	-	-	-	-	-
No. Analysts	-	-	-	-	-	15	14

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2026	2027
High	104.0M	48.0M
Avg	29.1M	18.4M
Low	6.9M	n/a

Revenue Growth

Revenue Growth	2026	2027
High	156.5%	64.9%
Avg	-28.2%	-36.8%
Low	-83.1%	-

EPS Forecast

EPS	2026	2027
High	-0.42	-0.30
Avg	-1.05	-1.00
Low	-1.33	-1.26

EPS Growth

EPS Growth	2026	2027
High	-	-
Avg	-	-
Low	-	-

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.